A composition for improving bone density, its preparation method, application and product thereof.

Abstract

This invention provides a composition for improving bone density, its preparation method, application, and product, belonging to the technical field of bone and joint health products. The composition for improving bone density comprises the following components in parts by weight: 0.1-70 parts collagen peptides; 0.01-2 parts casein phosphopeptides; 7-40 parts milk mineral salts; 0.5-40 parts fructooligosaccharides; and 0.01-1 parts vitamin D. In the composition provided by this invention, the casein phosphopeptides, vitamin D, fructooligosaccharides, collagen peptides, and milk mineral salts can interact to increase bone calcium and bone density, thus preventing or improving osteoporosis.

Description

Technical Field

[0001] This invention belongs to the technical field of bone and joint health products, and relates to a composition that improves bone density, specifically to a composition that improves bone density, its preparation method, application and product. Background Technology

[0002] Osteoporosis is one of the most common bone diseases, characterized by decreased bone mass, reduced bone strength, increased bone fragility, and susceptibility to fractures. Many variable and unvariable factors, including aging, lack of exercise, malnutrition, underlying diseases, medication intake, and bone loss in postmenopausal women, can contribute to osteoporosis. Therefore, improving osteoporosis is a crucial prerequisite for maintaining bone health. Research over the years has shown that specific nutritional supplements can regulate or stimulate specific functional goals in bone health, thereby exerting a therapeutic effect. In addition to medication, nutritional intervention offers a more cost-effective means of addressing bone diseases and their associated health costs.

[0003] Collagen peptides are a class of peptide mixtures obtained through the partial hydrolysis of collagen. In recent years, they have received widespread scientific attention as potential oral supplements for the recovery of tissues such as bones and joints. Collagen peptides can be digested in the intestine, cross the intestinal barrier, enter the circulatory system, and participate in metabolic processes in target tissues, exhibiting biological functions at the tissue level. They stimulate collagen synthesis in the extracellular matrix of cartilage and other tissues, improving bone metabolism.

[0004] Casein phosphopeptides are phosphorylated casein-derived peptides with a core amino acid sequence consisting of three phosphoserine residues and two glutamate residues, forming a negatively charged amino acid sequence. Multiple studies suggest that casein phosphopeptides can chelate with calcium ions through the negatively charged phosphoserine residues to form soluble complexes, thereby effectively inhibiting the formation of phosphate precipitation of calcium ions in the neutral or slightly alkaline environment of the small intestine. They can also increase the retention time of calcium ions in vivo, thus exerting a sustained-release effect.

[0005] Fructose is the only functional oligosaccharide possessing the dual physiological properties of a super-strong bifidus factor and water-soluble dietary fiber. As an excellent small-molecule water-soluble dietary fiber, fructooligosaccharides do not precipitate or increase food viscosity, and they have physiological functions such as regulating the gut microbiota. Fructose is almost impossible to break down by sucrase and maltase, therefore it cannot be digested and absorbed by the stomach and small intestine. Instead, it directly enters the colon, where it is fermented by the gut microbiota to produce organic acids. This lowers the pH in the intestine, creating an acidic environment and acidifying the contents of the intestinal lumen, increasing calcium solubility and thus promoting calcium absorption in the body, or by increasing the content of the calcium peptide d9k.

[0006] Bones are primarily composed of extracellular matrix proteins and osteocytes. The bone matrix is ​​mineralized through the physiological action of hydroxyapatite, and calcium is a major component of hydroxyapatite. The absorption and effective utilization of calcium significantly affect bone quality; therefore, calcium is often referred to as the body's vital metal. Calcium supplementation is considered a fundamental treatment for preventing and treating osteoporosis. Numerous studies have demonstrated that calcium supplementation can increase overall bone density and prevent bone loss that could lead to osteoporosis or fractures. Adequate calcium supplementation is beneficial for stabilizing bone quality.

[0007] Milk mineral salts, also known as milk calcium, are made from whey through purification, ultrafiltration, and drying processes. In addition to being rich in calcium, they also contain protein, lactose, and a balanced range of nutrients such as zinc, sodium, potassium, and magnesium.

[0008] Compared to calcium supplements such as calcium carbonate, calcium citrate, and calcium gluconate, which are widely used in the food industry, milk mineral salts exhibit superior bioavailability. Their calcium-to-phosphorus ratio is approximately 2:1, which is more conducive to human absorption and utilization. Furthermore, milk mineral salts have excellent sensory properties and are easy to combine with other products, making them an ideal dietary calcium source.

[0009] Vitamin D is a collective term for a group of steroid derivatives that have been considered synonymous with bone health since their discovery in the early 20th century. Vitamin D plays a vital role in calcium homeostasis and bone development and maintenance, and is widely recommended for preventing rickets, optimizing peak bone mass, and preventing bone loss. It may also reduce the risk of osteoporosis and fractures. In the body, vitamin D is generally believed to promote intestinal calcium absorption, regulate bone mineralization, and enhance the activity of osteocytes in the bone.

[0010] In summary, collagen peptides, casein phosphopeptides, fructooligosaccharides, milk mineral salts, and vitamin D can all be used as active substances in osteoporosis. However, the current application of these active substances suffers from problems such as low activity, complex formulations, complex preparation processes, and limited application.

[0011] Patent CN106578094A discloses a formula milk powder for preventing osteoporosis in the elderly, containing lactoferrin, hydrolyzed egg yolk powder, casein phosphopeptide, and milk mineral salts. It also contains whey protein powder, galactooligosaccharides, fructooligosaccharides, taurine, linoleic acid, α-linolenic acid, complex vitamins, and complex minerals. The complex vitamins include vitamins A, D, E, B1, B2, B6, and C. This formula milk powder, with the addition of milk mineral salts, can supplement the calcium needed by the human body. Furthermore, the addition of lactoferrin, hydrolyzed egg yolk powder, and casein phosphopeptide synergistically with the milk mineral salts to promote calcium absorption and utilization, promote osteoblast bone formation, and inhibit osteoclast bone resorption, achieving a dynamic balance between the two. This slows down and improves the progression of osteoporosis, protecting the bone health of the elderly. However, the formula of this invention has complex components, low activity, and limited application.

[0012] Chinese patent application CN113349379A discloses a composition and preparation method for improving bone health. The composition comprises the following components by weight: 20-55 parts non-denatured type II collagen; 10-20 parts enzymatically hydrolyzed bone powder; 1-10 parts hydrolyzed egg yolk powder; 2-10 parts hydrolyzed casein; 5-20 parts milk mineral salts; 0.1-3 parts colostrum basic protein; and 0.02-0.1 parts vitamin K2. The preparation method includes the following steps: weighing non-denatured type II collagen, enzymatically hydrolyzed bone powder, hydrolyzed egg yolk powder, hydrolyzed casein, milk mineral salts, colostrum basic protein, and vitamin K2, mixing them evenly to obtain a mixture; adding water and stirring evenly to obtain a mixed solution; refining the mixed solution by sequentially passing it through a colloid mill and a homogenizer; and spray-drying the homogenized solution to obtain the composition. This composition can activate the adsorption activity of osteoblasts, enabling calcium supplementation to enter and form bone. The milk mineral salts, combined with vitamin K2, can effectively improve calcium absorption and regulate bone health. However, the composition of this invention has a complex formulation and a complex preparation process.

[0013] Patent CN118511956A discloses a solid beverage containing frog bone collagen peptides, its preparation method, and its application. The solid beverage comprises frog bone collagen peptide powder, collagen peptides, milk mineral salts, arabinose, L-calcium lactate, ginger extract, steviol glycosides, taurine, xylitol, isomaltooligosaccharide, maltodextrin, vitamin C, casein phosphopeptide, theanine, edible flavoring, and stabilizers. The frog bone collagen peptide powder and the polypeptide components in the collagen peptides in the solid beverage have antioxidant and bone growth-promoting effects; calcium lactate, frog bone collagen peptide powder, and milk mineral salts provide a relatively large amount of calcium ions, providing a good nutritional environment for bone growth. However, the composition of this invention is complex, and it also introduces plant extracts, resulting in poor stability and a complex preparation process.

[0014] Therefore, the compositions disclosed above all have certain effects in improving osteoporosis or increasing bone density, but they have not completely solved the problems of low activity, complex composition, and certain limitations. Summary of the Invention

[0015] This invention addresses the problems existing in the prior art by providing a composition that improves bone density, its preparation method, and its application. This invention utilizes the interaction of casein phosphopeptide, vitamin D, fructooligosaccharides, collagen peptides, and milk mineral salts to increase bone calcium and bone density, and can be used to prevent or improve osteoporosis and improve bone density.

[0016] To achieve the above objectives, the technical solution adopted by the present invention is as follows:

[0017] In a first aspect, the present invention provides a composition having the effect of improving bone density, comprising the following components in parts by weight:

[0018]

[0019]

[0020] In the composition described herein, the collagen peptides can be any commercially available product and are not limited thereto. The collagen peptides are produced from fresh animal tissues (including skin, bone, tendons, ligaments, scales, etc.) rich in collagen, through extraction, hydrolysis, and purification, resulting in a product with a relative molecular mass of less than 10,000. The preferred mass fraction of the collagen peptides is 0.1-65 parts, more preferably 40-57 parts, more preferably 45-55 parts, and most preferably 51 parts.

[0021] In one embodiment, the collagen peptides are derived from animal bones, and the proportion of bone collagen peptides with a relative molecular mass of less than 10,000 is ≥90%.

[0022] In one embodiment, the collagen peptides are derived from bovine bone; the proportion of collagen peptides with a relative molecular mass of less than 10,000 is 92.78% by mass.

[0023] In one embodiment, the collagen peptide is selected from collagen peptides. The collagen peptides It is a specific collagen peptide with an average molecular weight of approximately 5 kDa, derived from the specific hydrolysis of collagen. Collagen peptide Multiple clinical trials have demonstrated that it can significantly increase bone density and help improve bone stability. The collagen peptides in the composition of this invention are preferably collagen peptides. The collagen peptides can stimulate connective tissue cells and target and regulate the metabolism of the body's own collagen. Together with calcium-supplementing components such as milk mineral salts, as well as calcium-absorbing components such as casein phosphopeptides, vitamin D, and fructooligosaccharides, they can significantly increase bone calcium and bone density.

[0024] In the composition, the casein phosphopeptide is preferably 0.14-1.21 parts by mass, more preferably 0.16-0.30 parts, and even more preferably 0.21 parts. The casein phosphopeptide can be obtained from bovine milk casein through enzymatic hydrolysis or bio-fermentation, or it can be a commercially available product; no limitation is made here. In one embodiment, the casein phosphopeptide in the composition is casein phosphopeptide with a purity of 80%, and the casein phosphopeptide is preferably 0.18-1.21 parts by mass, more preferably 0.20-0.30 parts, and even more preferably 0.26 parts.

[0025] In one embodiment, the casein phosphopeptide is derived from hydrolyzed casein peptide, wherein the casein phosphopeptide content in the hydrolyzed casein peptide is ≥3.5% by mass, and can be 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10%, 5%, or 3.5%.

[0026] Casein phosphopeptides have multiple benefits, including promoting mineral absorption, preventing tooth decay, promoting bone health, and enhancing immunity. The composition of this invention, through the synergistic effect of casein phosphopeptides, collagen peptides, milk mineral salts, vitamin D, and fructooligosaccharides, promotes calcium absorption and increases bone calcium and bone density, and can be used to prevent or improve osteoporosis.

[0027] In the composition, the milk mineral salt is preferably 12.2-20.5 parts by mass, more preferably 17-19 parts, and most preferably 17.6 parts. The milk mineral salt can be any commercially available product and is not limited thereto. In one embodiment, the milk mineral salt is derived from cow's milk, and the calcium content in the milk mineral salt is 23-28% by mass. The milk mineral salt in the composition includes the nutrient calcium, which can act as a calcium supplement. It works synergistically with calcium-absorbing components such as casein phosphopeptide, vitamin D, fructooligosaccharides, and collagen peptides to significantly increase bone calcium and bone density.

[0028] In the composition, the preferred mass fraction of fructooligosaccharides is 3.73-11.65 parts, more preferably 4-5 parts, and most preferably 4.61 parts. The fructooligosaccharides can be any commercially available product and are not limited thereto. In one embodiment, the fructooligosaccharides are derived from chicory, and the purity of the fructooligosaccharides is 93.2-97.5%. The fructooligosaccharides, in conjunction with casein phosphopeptides and collagen peptides, significantly increase bone calcium and bone density.

[0029] Preferably, the mass ratio of collagen peptides, casein phosphopeptides, and fructooligosaccharides is 0.1-70:0.01-2:0.5-30, more preferably 40-57:0.14-1.21:3.73-11.65, more preferably 45-55:0.16-0.30:4-5, and most preferably 51:0.26:4.61. The interaction between the components can significantly improve bone calcium and bone density.

[0030] In the composition, the vitamin D is selected from vitamin D or substances containing vitamin D, wherein the vitamin D includes vitamin D2 and / or vitamin D3, and the vitamin D-containing substance is selected from mushroom powder. In one embodiment, the vitamin D is selected from vitamin D3, and the active ingredient content of the vitamin D3 is 100,000 IU / g. The vitamin D3 can be any commercially available product and is not limited herein. The preferred mass fraction of vitamin D is 0.04-0.4 parts, more preferably 0.04-0.1 parts, and most preferably 0.04 parts. This invention, by combining vitamin D with casein phosphopeptide, collagen peptide, fructooligosaccharide, and milk mineral salts, supplements calcium, promotes calcium absorption, and increases bone calcium and bone density, and can be used to prevent or improve osteoporosis.

[0031] Preferably, in the composition, the mass ratio of collagen peptides, casein phosphopeptides, milk mineral salts, fructooligosaccharides, and vitamin D is 0.1-70:0.01-2:7-30:0.5-30:0.01-0.5, more preferably 40-57:0.14-1.21:12.2-20.5:0.5-30:0.04-0.4, even more preferably 45-55:0.16-0.30:17-19:3.73-11.65:0.04-0.4, and most preferably 51:0.21:17.6:4.61:0.04.

[0032] In one embodiment, the composition further includes excipients, which are common types of excipients and may be one or more of food additives and fruit and vegetable powders. The food additives include, but are not limited to: nutritional fortifiers, preservatives, antioxidants, flavor enhancers, thickeners, acidity regulators, emulsifiers, and colorants. The fruit and vegetable powders include, but are not limited to: coconut milk powder, mango powder, orange powder, strawberry powder, banana powder, and passion fruit powder.

[0033] In one embodiment, the composition further includes excipients, which include one or more of food additives and fruit and vegetable powders, wherein the food additives include sweeteners and thickeners, the fruit and vegetable powders include coconut milk powder, the sweeteners include erythritol and / or mogroside, and the thickeners include xanthan gum.

[0034] In one embodiment, the composition further includes excipients, including coconut milk powder, erythritol, mogroside, and xanthan gum, wherein the mass ratio of erythritol to mogroside is 1:1.

[0035] In one embodiment, the composition further includes excipients, wherein the excipients are present in parts by weight of 5-45 parts, preferably 10-30 parts, and more preferably 20-25 parts.

[0036] In one embodiment, the composition further includes excipients, including fruit and vegetable powders, xanthan gum, and sweeteners. The fruit and vegetable powders include coconut milk powder, with a mass fraction of 5-25 parts, preferably 8-15 parts, and more preferably 10 parts. The xanthan gum has a mass fraction of 0.1-2 parts, preferably 0.2-1 parts. The sweetener has a mass fraction of 0.5-15 parts, preferably 5-10 parts, and more preferably 10 parts.

[0037] Secondly, the present invention provides a method for preparing the composition described in the above-mentioned technical solution, comprising:

[0038] The components are mixed to obtain the composition that improves bone density.

[0039] Thirdly, the present invention provides the application of the composition described in the above-described technical solution or the composition prepared by the preparation method described in the above-described technical solution in the preparation of products for preventing or improving osteoporosis.

[0040] Fourthly, the present invention provides a product for preventing or improving osteoporosis, comprising the composition described in the above technical solution or the composition prepared by the preparation method described in the above technical solution.

[0041] Compared with the prior art, the present invention has the following beneficial effects:

[0042] Firstly, in the composition provided by this invention, collagen peptides can stimulate connective tissue cells and target and regulate the metabolism of the body's own collagen. Together with casein phosphopeptides, fructooligosaccharides, vitamin D, and milk mineral salts, they can supplement calcium, promote calcium absorption, and regulate the metabolism of the body's own collagen, thereby achieving the effect of increasing bone calcium and bone density. This can be used to prevent or improve osteoporosis.

[0043] Secondly, in the composition provided by the present invention, collagen peptides, casein phosphopeptides and oligofructose interact with each other in a mass ratio of 0.1-70:0.01-2:0.5-40. This interaction can supplement calcium, promote calcium absorption, regulate the metabolism of collagen, significantly increase bone calcium and bone density, and alleviate weight gain caused by decreased estrogen levels.

[0044] Third, the composition provided by the present invention has good stability, low moisture absorption, and can be stored for a long time, thus extending its shelf life. Detailed Implementation

[0045] It is worth noting that, unless otherwise specified, the raw materials used in this invention are all commercially available products, and their sources are not specifically limited.

[0046] The following sources of raw materials are provided as examples:

[0047] Collagen peptides: Collagen peptides Jialida;

[0048] Casein phosphopeptide: Shanghai Kanglang Biotechnology Co., Ltd., purity specification: BR, 80%;

[0049] Milk mineral salts: Guangzhou Huijian Biotechnology Co., Ltd., Product No.: 20181016-27;

[0050] Fructooligosaccharides: Baolingbao Biotechnology Co., Ltd.;

[0051] Vitamin D3: Vitamin D3 powder, Zhejiang Kangpuda Biotechnology Co., Ltd.

[0052] Examples 1-5

[0053] Weigh out collagen peptides, casein phosphopeptides, milk mineral salts, fructooligosaccharides, and vitamin D3 according to the formula in Table 1, mix them evenly, and obtain a composition that improves bone density.

[0054] Table 1. Formulations of compositions that improve bone density

[0055]

[0056]

[0057] Comparative Example 1

[0058] The difference from Example 1 is that the "collagen peptide" in Example 1 is replaced with the same number of parts by mass of "casein phosphopeptide" to obtain a composition that improves bone density.

[0059] Comparative Example 2

[0060] The difference from Example 1 is that "51 parts collagen peptides, 0.26 parts casein phosphopeptides, and 4.61 parts fructooligosaccharides" in Example 1 are replaced with "20 parts collagen peptides". "35.5 parts casein phosphopeptide and 0.37 parts fructooligosaccharide" to obtain a composition that improves bone density.

[0061] Comparative Example 3

[0062] The difference from Example 1 is that the "51 parts collagen peptide, 0.26 parts casein phosphopeptide, and 4.61 parts fructooligosaccharide" in Example 1 are replaced with "18 parts collagen peptide, 28 parts casein phosphopeptide, and 9.87 parts fructooligosaccharide" to obtain a composition that improves bone density.

[0063] Comparative Example 4

[0064] The composition for improving bone mineral density consists of the following components in parts by weight:

[0065] 19 parts collagen peptides, 6.7 parts casein phosphopeptides, 46 parts milk mineral salts, 0.3 parts fructooligosaccharides, and 1.51 parts vitamin D3.

[0066] The components were mixed evenly according to the method of Example 1 to obtain a composition that improves bone density.

[0067] Experimental Example 1

[0068] Body weight, bone calcium content, and bone density were tested according to the "Methods for Functional Testing and Evaluation of Health Foods (2023 Edition)". The specific steps are as follows:

[0069] One hundred and ten healthy SPF-grade female SD rats, weighing approximately 250 ± 15 g, were selected and, after acclimatization for 5 days, randomly divided into 11 groups of 10 rats each: sham-operated group, model group, Examples 1-5 groups, and Comparative Examples 1-4 groups. Except for the sham-operated group, all other groups underwent bilateral ovariectomy. The sham-operated group underwent the same surgical procedure but without ovariectomy. Postoperatively, the sham-operated and model groups were given free access to water in addition to their normal diet. The Examples 1-5 and Comparative Examples 1-4 groups were given 0.2 g / day (equivalent to 5 times the recommended human dose) of the combination of Examples 1-5 and Comparative Examples 1-4, respectively, via gavage for 3 months, in addition to their normal diet and water intake. The following measurements were then performed:

[0070] 1. Weight measurement:

[0071] Weight was measured after 12 hours of fasting.

[0072] As shown in Table 2, the results indicate that ovariectomy in rats leads to a decrease in estrogen levels and an increase in body weight. Compared with the model group, the body weight of rats treated with the compositions of Examples 1-5 of this invention was significantly reduced.

[0073] Table 2 Results of rat weight measurement

[0074] Group Initial body weight (g) Weight in the 3rd month (g) Sham surgery group 252.68±10.04 335.05±15.53 Model group 253.71±11.21 396.35±7.26 Example 1 251.45±9.35 <![CDATA[355.62±22.91 ** ]]> Example 2 250.65±11.07 <![CDATA[363.82±13.42 * ]]> Example 3 245.36±12.23 <![CDATA[361.25±9.26 * ]]> Example 4 249.41±10.22 <![CDATA[370.62±13.92 * ]]> Example 5 251.85±9.11 <![CDATA[372.62±15.19 * ]]> Comparative Example 1 250.51±10.57 392.83±14.21 Comparative Example 2 250.79±12.65 385.76±13.99 Comparative Example 3 255.65±11.38 377.82±11.75 Comparative Example 4 249.69±10.25 390.96±13.92

[0075] Note: *The representative group showed a significant difference from the model group (p < 0.05). ** The representative group showed a significant difference from the model group (p < 0.01).

[0076] 2. Bone calcium measurement

[0077] (1) Sample collection and preparation

[0078] The left femur of a rat was dried in an oven at 105℃ until constant weight, and the dry weight of the bone was weighed and placed in an Erlenmeyer flask for digestion.

[0079] (2) Sample digestion

[0080] Based on the calcium content in the sample, accurately weigh 0.5g and place it in a 150mL Erlenmeyer flask. Cover the flask with a small funnel and add 15mL of mixed acid (nitric acid: perchloric acid = 4:1). Heat on a hot plate until it produces white fumes and becomes transparent and colorless. If the acid solution is insufficient, add a small amount of mixed acid.

[0081] After the digestion solution becomes clear and colorless, add a few milliliters of deionized water and boil to remove any remaining acid. Repeat twice, ensuring the final volume of the digestion solution does not exceed 1 mL. A blank test should be performed simultaneously with the sample digestion, adding the same volume of mixed acid as used in the sample digestion and digesting under the same conditions.

[0082] (3) Measurement

[0083] Atomic absorption spectrometry was used to determine bone calcium content.

[0084] Table 3 shows the results of bone calcium content determination. The results indicate that ovariectomy in rats led to a decrease in estrogen levels and a reduction in bone calcium content. Compared with the model group, the bone calcium content of rats treated with the compositions of Examples 1-5 of this invention was significantly increased. Comparison of bone mineral density in rats treated with the compositions of Examples 1 and 1-4 revealed that the combined action of milk mineral salts, collagen peptides, hydrolyzed casein peptides, vitamin D3, and fructooligosaccharides in the compositions of this invention can significantly increase bone calcium content and can be used to improve osteoporosis.

[0085] Table 3 Results of rat bone calcium determination

[0086] Group Bone calcium content (mg / g) Sham surgery group 265.1±20.4 Model group 204.2±15.9 Example 1 <![CDATA[261.2±11.2 ** ]]> Example 2 <![CDATA[254.8±22.3 * ]]> Example 3 <![CDATA[252.1±21.4 * ]]> Example 4 <![CDATA[243.2±19.5 * ]]> Example 5 <![CDATA[246.4±17.1 * ]]> Comparative Example 1 218.5±15.0 Comparative Example 2 233.8±11.7 Comparative Example 3 237.2±18.5 Comparative Example 4 220.9±19.3

[0087] Note: * The representative group showed a significant difference from the model group (p < 0.05). ** The representative group showed a significant difference from the model group (p < 0.01).

[0088] 3. Bone mineral density measurement:

[0089] Bone mineral density at the center point and distal end of the femur was measured using a bone densitometer.

[0090] (1) Mark the distal end of the femur and the midpoint of the femur to determine the measurement points.

[0091] Determining the midpoint of the femur: Measure the entire length of the femur, and draw a straight line along the cross-sectional direction through its midpoint. This is the midpoint of the femur (cross-section).

[0092] Determining the measurement point at the distal end of the femur: Determine the measurement point at the lowest edge of the articular groove at the distal end of the femur. Draw a straight line parallel to the mark at the midpoint of the femur mentioned above through this point. This is the measurement point (section) at the distal end of the femur.

[0093] (2) The instrument is calibrated using a bone model before measurement.

[0094] (3) After calibration, the bone model should be measured and compared with its standard value. The error should not exceed 3%.

[0095] (4) Bone densitometer parameter settings:

[0096] Measurement method: Precision; Number of scans: 2; Scanning mode: Automatic; Detection threshold: 99%.

[0097] (5) Measure bone mineral density at the midpoint and distal end of the femur.

[0098] The right femur of a rat was used as the test bone. The bone was placed on the measuring platform perpendicular to the direction of movement of the bone densitometer probe. The bone was moved until the marked line at the test point coincided with the vertical projection of the probe's trajectory onto the measuring platform. Measurements were then taken, with each point measured twice. If the two results were not parallel (error greater than 10%), the measurement was repeated. The average of the two results was calculated, and the result (BMD) was divided by the bone width (BW) by the bone mineral content (BMC).

[0099] The bone mineral density (BMD) measurements are shown in Table 4. The results indicate that ovariectomy in rats led to a decrease in estrogen levels and a reduction in BMD at the femoral midpoint and distal femur. Compared with the model group, the BMD of rats treated with the compositions of Examples 1-5 of this invention was significantly increased. Comparing the BMD of rats treated with the compositions of Examples 1 and 1-4, it was found that the milk mineral salts, collagen peptides, hydrolyzed casein peptides, vitamin D3, and fructooligosaccharides in the compositions of this invention work together to significantly increase BMD and can be used to improve osteoporosis.

[0100] Table 4 Results of rat bone mineral density measurement

[0101]

[0102]

[0103] Note: *The representative group showed a significant difference from the model group (p < 0.05). ** The representative group showed a significant difference from the model group (p < 0.01).

[0104] Experimental Example 2

[0105] The excipients were added to the compositions of Examples 1-5 and Comparative Examples 1-4 respectively to obtain compositions containing excipients. The excipients were 10 parts coconut milk powder, 0.75 parts xanthan gum, and 10 parts sweetener (erythritol and mogroside in a mass ratio of 1:1).

[0106] Take a glass desiccator containing a supersaturated NaCl solution at the bottom. The desiccator contains nine weighing bottles. Bring the desiccator to a constant weight in a 25°C drying oven. Take 1g of each composition containing excipients, place it in a weighing bottle, weigh it accurately, open the weighing lid, place the bottle on top of the desiccator, and store it in a 25°C drying oven. Weigh the bottle after 15 days and calculate the moisture absorption rate of different samples.

[0107] Moisture absorption rate (%) = (Weight of composition after 15 days - Initial weight of composition) / Initial weight of composition * 100%

[0108] The results are shown in Table 5. The results show that the composition of the present invention, after adding the same excipients, has low moisture absorption, good stability, and can be stored for a long time, thus extending the shelf life.

[0109] Table 5. Hygroscopicity results of compositions containing excipients

[0110]

[0111]

[0112] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, and is not intended to limit the scope of protection of the present invention. Simple modifications or equivalent substitutions made by those skilled in the art to the technical solution of the present invention do not depart from the essence and scope of the technical solution of the present invention.

Claims

1. A composition having the effect of improving bone density, characterized in that, It is made from the following components in parts by weight: Collagen peptides 0.1-70 parts; Casein phosphopeptide 0.01-2 parts; Milk mineral salts 7-40 parts; Fructooligosaccharides 0.5-40 parts; Vitamin D 0.01-1 serving; The mass ratio of collagen peptides, casein phosphopeptides, and fructooligosaccharides is 40-57:0.14-1.21:3.73-11.

65.

2. The composition according to claim 1, characterized in that, The mass ratio of collagen peptides, casein phosphopeptides, and fructooligosaccharides is 45-55:0.16-0.30:4-5.

3. The composition according to claim 1, characterized in that, The vitamin D is selected from vitamin D2, vitamin D3, or substances containing vitamin D; the substance containing vitamin D is selected from mushroom powder.

4. The composition according to claim 1, characterized in that, The composition also includes excipients.

5. A method for preparing the composition according to any one of claims 1-4, characterized in that, include: The components are mixed to obtain the composition that improves bone density.

6. The use of the composition according to any one of claims 1-4 or the composition prepared by the preparation method according to claim 5 in the preparation of products for preventing or improving osteoporosis.

7. A product for preventing or improving osteoporosis, characterized in that, include: The composition according to any one of claims 1-4 or the composition prepared by the preparation method according to claim 5.

Images